HUP0400932A3 - Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same - Google Patents
Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the sameInfo
- Publication number
- HUP0400932A3 HUP0400932A3 HU0400932A HUP0400932A HUP0400932A3 HU P0400932 A3 HUP0400932 A3 HU P0400932A3 HU 0400932 A HU0400932 A HU 0400932A HU P0400932 A HUP0400932 A HU P0400932A HU P0400932 A3 HUP0400932 A3 HU P0400932A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical composition
- composition containing
- same
- antidiabetic compound
- Prior art date
Links
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title 1
- 229960000698 nateglinide Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39836499A | 1999-09-17 | 1999-09-17 | |
US54548000A | 2000-04-07 | 2000-04-07 | |
GB0021055A GB0021055D0 (en) | 2000-08-26 | 2000-08-26 | Method of treating metabolic disorders,espicially diabetes,or a disease or condition associated with diabetes |
PCT/EP2000/009074 WO2001021159A2 (en) | 1999-09-17 | 2000-09-15 | Pharmaceutical composition of nateglinide and another antidiabetcagent |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0400932A2 HUP0400932A2 (hu) | 2004-07-28 |
HUP0400932A3 true HUP0400932A3 (en) | 2007-11-28 |
Family
ID=27255861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400932A HUP0400932A3 (en) | 1999-09-17 | 2000-09-15 | Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1212077A2 (hu) |
JP (2) | JP2003509457A (hu) |
KR (2) | KR100544244B1 (hu) |
CN (1) | CN1309380C (hu) |
AR (3) | AR028299A1 (hu) |
AU (1) | AU7904400A (hu) |
BE (1) | BE1013726A5 (hu) |
BR (1) | BR0014525A (hu) |
CA (1) | CA2381992C (hu) |
CO (1) | CO5200844A1 (hu) |
CZ (1) | CZ20011723A3 (hu) |
FI (1) | FI20010683A (hu) |
FR (1) | FR2798592B1 (hu) |
HK (1) | HK1046101A1 (hu) |
HU (1) | HUP0400932A3 (hu) |
IL (1) | IL148168A0 (hu) |
MY (2) | MY143051A (hu) |
NO (1) | NO20021197L (hu) |
NZ (2) | NZ517280A (hu) |
PE (1) | PE20010739A1 (hu) |
PL (1) | PL354168A1 (hu) |
SG (1) | SG127714A1 (hu) |
SK (1) | SK3602002A3 (hu) |
TW (2) | TWI278311B (hu) |
WO (1) | WO2001021159A2 (hu) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
HUP0204109A3 (en) * | 1999-12-28 | 2004-06-28 | Ajinomoto Kk | Oral preparations for diabetes |
MXPA02009130A (es) * | 2000-03-17 | 2003-03-12 | Ajinomoto Kk | Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos. |
FR2809310B1 (fr) * | 2000-05-26 | 2004-02-13 | Centre Nat Rech Scient | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
WO2002072146A2 (en) * | 2001-03-12 | 2002-09-19 | Novartis Ag | Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
FR2826278B1 (fr) * | 2001-06-20 | 2005-03-25 | Lipha | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
ES2275889T3 (es) * | 2001-06-20 | 2007-06-16 | Merck Sante | Utilizacion de agentes antidiabeticos para fabricar un medicamento que tiene un efecto cicatrizante. |
BR0308316A (pt) * | 2002-03-11 | 2004-12-28 | Novartis Ag | Sais de nateglinida |
IL164222A0 (en) | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
JP4433496B2 (ja) * | 2002-05-28 | 2010-03-17 | 味の素株式会社 | Atpクエン酸リアーゼの発現抑制用医薬組成物及びその使用 |
US6830759B2 (en) | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
US7420084B2 (en) | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
WO2005013964A1 (ja) * | 2003-08-08 | 2005-02-17 | Ajinomoto Co., Inc. | ナテグリニド含有製剤 |
WO2005094812A1 (ja) * | 2004-04-01 | 2005-10-13 | Ajinomoto Co., Inc. | ナテグリニド含有製剤 |
BR122018075478B8 (pt) | 2004-06-24 | 2023-10-31 | Vertex Pharma | moduladores de transportadores de cassete de ligação de atp |
WO2006016602A1 (ja) * | 2004-08-10 | 2006-02-16 | Ajinomoto Co., Inc. | 苦味の低減したナテグリニド含有製剤 |
HUE049976T2 (hu) | 2005-12-28 | 2020-11-30 | Vertex Pharma | N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói |
US20090318502A1 (en) * | 2006-03-22 | 2009-12-24 | Intranasal Therapeutics, Inc. | Pharmaceutical Compositions Comprising a Hypoglycemic Agent and Methods of Using Same |
WO2010054286A2 (en) * | 2008-11-10 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
WO2010060041A2 (en) * | 2008-11-21 | 2010-05-27 | Auspex Pharmaceuticals, Inc. | Phenylalanine amide inhibitors of atp-sensitive potassium channels |
EP2408750B1 (en) | 2009-03-20 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
KR101035574B1 (ko) * | 2009-04-09 | 2011-05-23 | 대한민국 | 제 2형 당뇨병 치료효과를 판정하는 방법 |
TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
HUE051738T2 (hu) | 2011-01-07 | 2021-03-29 | Anji Pharma Us Llc | Kemoszenzoros receptorligandum-alapú terápiák |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
WO2013066277A1 (en) * | 2011-11-03 | 2013-05-10 | Mahmut Bilgic | Synergic compositions |
WO2013077820A1 (en) * | 2011-11-23 | 2013-05-30 | Mahmut Bilgic | Treatment package composed of dosage forms comprising nateglinide -metformin hydrochloride |
MX2014008190A (es) | 2012-01-06 | 2015-02-04 | Elcelyx Therapeutics Inc | Composiciones de biguanida y métodos para tratar transtornos metabólicos. |
AU2013207329B2 (en) | 2012-01-06 | 2017-10-26 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 薬学的組成物およびその投与 |
ES2702288T3 (es) | 2014-10-07 | 2019-02-28 | Vertex Pharma | Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística |
CN105646332B (zh) * | 2014-11-09 | 2018-05-25 | 复旦大学 | 氨基甲基哌啶类衍生物及其制备方法和药物用途 |
CN114099520A (zh) * | 2021-12-31 | 2022-03-01 | 中国药科大学 | 格列喹酮用于制备治疗溃疡性结肠炎的药物的用途 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3561444A (en) | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
US3703173A (en) | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS55129221A (en) * | 1979-03-29 | 1980-10-06 | Kaken Pharmaceut Co Ltd | Preparation of oral preparation containing hardly soluble medicine |
JPS55129220A (en) * | 1980-02-08 | 1980-10-06 | Yamanouchi Pharmaceut Co Ltd | Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability |
JPS56110612A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Readily disintegrable and absorbable compression molded article of slightly soluble drug |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US5216167A (en) | 1983-12-30 | 1993-06-01 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
US4635627A (en) | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
WO1986007056A1 (en) | 1985-05-21 | 1986-12-04 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
US4806359A (en) * | 1987-04-22 | 1989-02-21 | Mcneilab, Inc. | Iburprofen sustained release matrix and process |
EP0842925A1 (en) | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
WO1989008651A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
US4997948A (en) | 1989-10-27 | 1991-03-05 | American Home Products | 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
ATE149483T1 (de) | 1991-07-30 | 1997-03-15 | Ajinomoto Kk | Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung |
US5463116A (en) | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
JP2845743B2 (ja) | 1992-12-28 | 1999-01-13 | 三菱化学株式会社 | 新規なナフタレン誘導体 |
JPH0776516A (ja) * | 1993-09-06 | 1995-03-20 | Toyobo Co Ltd | 難溶性薬物含有製剤の製造方法 |
JPH07126154A (ja) * | 1993-10-29 | 1995-05-16 | Terumo Corp | 難水溶性医薬品含有医薬製剤 |
US5488510A (en) | 1994-07-26 | 1996-01-30 | Lemay; Edward J. | Enhanced depth perception viewing device for television |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
JP4010377B2 (ja) | 1996-09-06 | 2007-11-21 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
DE19637082A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
WO1998022105A1 (fr) * | 1996-11-15 | 1998-05-28 | Ajinomoto Co., Inc. | Preparation en comprimes |
DK1011673T3 (da) * | 1997-06-13 | 2001-07-09 | Novo Nordisk As | Hidtil ukendt metode til behandling af nidom |
-
2000
- 2000-09-14 AR ARP000104821A patent/AR028299A1/es not_active Application Discontinuation
- 2000-09-14 CO CO00069666A patent/CO5200844A1/es not_active Application Discontinuation
- 2000-09-15 WO PCT/EP2000/009074 patent/WO2001021159A2/en active IP Right Grant
- 2000-09-15 KR KR1020047010952A patent/KR100544244B1/ko not_active IP Right Cessation
- 2000-09-15 CA CA2381992A patent/CA2381992C/en not_active Expired - Fee Related
- 2000-09-15 NZ NZ517280A patent/NZ517280A/en not_active IP Right Cessation
- 2000-09-15 BE BE2000/0585A patent/BE1013726A5/fr not_active IP Right Cessation
- 2000-09-15 NZ NZ528738A patent/NZ528738A/en not_active IP Right Cessation
- 2000-09-15 CN CNB008019762A patent/CN1309380C/zh not_active Expired - Lifetime
- 2000-09-15 TW TW089118960A patent/TWI278311B/zh not_active IP Right Cessation
- 2000-09-15 JP JP2001524585A patent/JP2003509457A/ja not_active Withdrawn
- 2000-09-15 TW TW092125226A patent/TWI278312B/zh not_active IP Right Cessation
- 2000-09-15 SG SG200401291A patent/SG127714A1/en unknown
- 2000-09-15 AU AU79044/00A patent/AU7904400A/en not_active Abandoned
- 2000-09-15 EP EP00969260A patent/EP1212077A2/en not_active Ceased
- 2000-09-15 PE PE2000000955A patent/PE20010739A1/es not_active Application Discontinuation
- 2000-09-15 FR FR0011782A patent/FR2798592B1/fr not_active Expired - Fee Related
- 2000-09-15 EP EP08167253A patent/EP2011507A2/en not_active Withdrawn
- 2000-09-15 KR KR10-2002-7003551A patent/KR100506428B1/ko not_active IP Right Cessation
- 2000-09-15 SK SK360-2002A patent/SK3602002A3/sk unknown
- 2000-09-15 HU HU0400932A patent/HUP0400932A3/hu unknown
- 2000-09-15 MY MYPI20050152A patent/MY143051A/en unknown
- 2000-09-15 CZ CZ20011723A patent/CZ20011723A3/cs unknown
- 2000-09-15 BR BR0014525-4A patent/BR0014525A/pt not_active IP Right Cessation
- 2000-09-15 PL PL00354168A patent/PL354168A1/xx not_active Application Discontinuation
- 2000-09-15 IL IL14816800A patent/IL148168A0/xx unknown
- 2000-09-15 MY MYPI20004314A patent/MY131810A/en unknown
-
2001
- 2001-02-05 AR ARP010100516A patent/AR028504A2/es unknown
- 2001-04-02 FI FI20010683A patent/FI20010683A/fi not_active Application Discontinuation
-
2002
- 2002-03-11 NO NO20021197A patent/NO20021197L/no unknown
- 2002-10-25 HK HK02107767.4A patent/HK1046101A1/zh unknown
-
2006
- 2006-09-06 JP JP2006241423A patent/JP2006335767A/ja active Pending
-
2009
- 2009-07-28 AR ARP090102868A patent/AR072329A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400932A3 (en) | Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same | |
HUP0203766A3 (en) | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof and pharmaceutical compositions containing them | |
HUP0203902A3 (en) | Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use | |
HUP0001539A3 (en) | 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same | |
HUP0203542A3 (en) | 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same | |
EG24142A (en) | Crystalline monohydrate, process for the preparation thereof and the use thereof for preparing a pharmaceutical composition | |
HUP0201376A2 (en) | Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds | |
HUP0200714A3 (en) | Pharmaceutical compounds, pharmaceutical compositions containing them and their use | |
IL135920A0 (en) | 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor | |
HUP0001508A3 (en) | 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them | |
IL138280A0 (en) | 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF | |
IL140897A0 (en) | Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL148870A (en) | 2'-substituted 1,1'-biphenyl - 2 - carbonamides, method for the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds | |
HUP0105108A3 (en) | Amide compounds, process for their preparation and pharmaceutical compositions containing them | |
IL156662A0 (en) | Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same | |
HUP0105313A3 (en) | Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use | |
IL165012A0 (en) | (S)-4-Amino-5-chloro-2-methoxy-N-Ä1-(-tetrahydrofurylcarbonyl)-4-piperidinylmethylÜ-4-piperidinylÜbenzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | |
HUP0102215A3 (en) | Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation | |
IL137494A0 (en) | Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same | |
HUP0203597A3 (en) | Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use | |
HUP9803040A3 (en) | Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them | |
HUP0202736A3 (en) | Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof | |
HK1040980A1 (zh) | 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途 | |
HUP0104033A3 (en) | 1-benzoyl-tetrahydropyridazine derivatives, process for their preparation, their use and medicaments containing the compounds | |
HUP0200121A3 (en) | Calcilytic compounds, pharmaceutical compositions containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |